BRCA1 and neoplasm: The MyChoice HRD assay assesses BRCA1/2 sequences and genomic scarring and calculates an HRD score comprising three biomarkers: loss of heterozygosity (LOH) (>15 Mb but shorter than the whole chromosome), telomeric allelic imbalance (TAI) (allelic imbalance not crossing the centromere but extending to the subtelomere) and large‐scale state transitions (LSTs) (chromosomal breaks between adjacent regions of >10 Mb after filtering variations of ≤3 Mb).79, 80 Tumours were scored on a scale of 0–100 with a cut‐off score of 42.